Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis

被引:6
|
作者
Baum, Joanna [1 ,2 ,3 ,4 ,5 ]
Braicu, Elena Ioana [1 ,2 ,3 ,4 ,5 ]
Hunsicker, Oliver [2 ,3 ,4 ,6 ]
Vergote, Ignace [5 ,7 ]
Concin, Nicole [5 ,8 ]
Van Nieuwenhuysen, Els [5 ,7 ]
Feldheiser, Aarne [2 ,3 ,4 ,6 ]
Achimas-Cadariu, Patriciu [5 ,9 ]
Darb-Esfahani, Silvia [5 ,10 ]
Berger, Astrid [5 ,8 ]
Fetica, Bogdan [5 ,11 ]
Mahner, Sven [5 ,12 ,13 ]
Papadia, Andrea [14 ,15 ,16 ]
Woelber, Linn [5 ,13 ]
Gasparri, Maria Luisa [14 ,15 ,16 ]
Vanderstichele, Adriaan [5 ,7 ]
Panici, Pierluigi Benedetti [17 ]
Mueller, Michael D. [15 ,16 ]
Ruscito, Ilary [1 ,2 ,3 ,4 ,18 ]
Woopen, Hannah [1 ,2 ,3 ,4 ,5 ]
Sehouli, Jalid [1 ,2 ,3 ,4 ,5 ]
机构
[1] Charite Univ Med Berlin, Dept Gynecol, European Competence Ctr Ovarian Canc, Campus Virchow Klinikum, Berlin, Germany
[2] Free Univ Berlin, Berlin, Germany
[3] Humboldt Univ, Berlin, Germany
[4] Berlin Inst Hlth, Berlin, Germany
[5] Tumorbank Ovarian Canc Network, Berlin, Germany
[6] CCM CVK Charite Univ Med Berlin, Dept Anaesthesiol & Intens Care Med, Berlin, Germany
[7] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven Canc Inst, Dept Gynecol & Obstet, Leuven, Belgium
[8] Innsbruck Med Univ, Dept Gynecol & Obstet, Innsbruck, Austria
[9] Univ Med & Pharm Iuliu Hatieganu Cluj Napoca, Oncol Inst Cluj Napoca, Dept Surg & Gynecol Oncol, Cluj Napoca, Romania
[10] Charite Univ Med Berlin, Inst Pathol, Berlin, Germany
[11] Oncol Inst Prof Dr Ion Chiricuta, Dept Pathol, Cluj Napoca, Romania
[12] Ludwig Maximilians Univ Munchen, Dept Obstet & Gynecol, Univ Hosp, Munich, Germany
[13] Univ Klinikum Hamburg Eppendorf, Dept Gynecol, Hamburg, Germany
[14] Univ Italian Switzerland USI, Dept Obstet & Gynecol, Ente Osped Cantonale Lugano, Lugano, Switzerland
[15] Univ Hosp Bern, Dept Obstet & Gynecol, Bern, Switzerland
[16] Univ Bern, Bern, Switzerland
[17] Univ Sapienza Roma, Dept Gynecol Obstet & Urol, Rome, Italy
[18] Sapienza Univ Rome, St Andrea Univ Hosp, Dept Med & Surg Sci & Translat Med, Gynecol Div, Rome, Italy
关键词
ovary; gynecologic surgical procedures; BRCA1; protein; intestines; surgical procedures; operative; ADVANCED-STAGE OVARIAN; SURGERY; CYTOREDUCTION; CARCINOMA; DISEASE;
D O I
10.1136/ijgc-2020-002023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Long-term survivors of ovarian cancer are a unique group of patients in whom prognostic factors for long-term survival have been poorly described. Such factors may provide information for a more personalized therapeutic approach. The objective of this study is to determine further characteristics of long-term survivors with high-grade serous ovarian cancer. Methods Long-term survivors were defined as patients living longer than 8 years after first diagnosis and were recruited within seven high volume centers across Europe from November 1988 to November 2008. The control group included patients with high-grade serous ovarian cancer with less than 5 years' survival identified from the systematic 'Tumorbank ovarian cancer' database. A subanalysis of Charite patients only was performed separately for in-depth analysis of tumor dissemination. Propensity score matching with nearest-neighbor caliper width was used to match long-term survivors and the control group regarding age, FIGO stage, and residual tumor. Results A total of 276 patients with high-grade serous ovarian cancer were included, divided into 131 long-term survivors and 145 control group patients. After propensity score matching and multivariable adjustment, platinum sensitivity (p=0.002) was an independent favorable prognostic factor whereas recurrence (p<0.001) and ascites (p=0.021) were independent detrimental predictors for long-term survival. Significantly more long-term survivors tested positive for mutation in the BRCA1 gene than the BRCA2 gene (p=0.016). Intraoperatively, these patients had less tumor involvement of the upper abdomen at initial surgery (p=0.024). Complexity of surgery and surgical techniques were similar in both cohorts. Conclusion Platinum sensitivity constitutes a favorable factor for long-term survival whereas tumor involvement of the upper abdomen, ascites, and recurrence have a negative impact. Based on clinical estimation, long-term survival is associated with combinations of clinical, surgical, and molecular factors.
引用
收藏
页码:713 / 720
页数:8
相关论文
共 50 条
  • [21] MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer
    Baath, Maria
    Jonsson, Jenny-Maria
    Fremer, Sofia Westbom
    de la Fuente, Laura Martin
    Tran, Lena
    Malander, Susanne
    Kannisto, Paivi
    Masback, Anna
    Honeth, Gabriella
    Hedenfalk, Ingrid
    [J]. GENES, 2021, 12 (05)
  • [22] Determinants of clinical outcome in high grade serous ovarian cancer
    Bowtell, David D. L.
    Cown, Prue
    Etemadmoghadam, Dariush
    Alsop, Kathryn
    George, Joshy
    de Fazaio, Anna
    Mitchell, Gillian
    [J]. CANCER RESEARCH, 2012, 72
  • [23] BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study
    Petrillo, Marco
    Marchetti, Claudia
    De Leo, Rossella
    Musella, Angela
    Capoluongo, Ettore
    Paris, Ida
    Panici, Pierluigi Benedetti
    Scambia, Giovanni
    Fagotti, Anna
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2017, 217 (03) : 334.e1 - 334.e9
  • [24] A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer
    Jin, Chengjuan
    Xue, Yingfeng
    Li, Yingwei
    Bu, Hualei
    Yu, Hongfeng
    Zhang, Tao
    Zhang, Zhiwei
    Yan, Shi
    Lu, Nan
    Kong, Beihua
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (01) : 51 - 58
  • [25] Predictive and prognostic immunologic factors in high-grade serous ovarian cancer
    Ayub, T. H.
    Riemann, S.
    Keyver-Paik, M. -D.
    Kuhn, W.
    Barchet, W.
    Kubler, K.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 195 - 196
  • [26] Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer
    Trudel, Dominique
    Avarvarei, Luminita-Mihaela
    Orain, Michele
    Turcotte, Stephane
    Plante, Marie
    Gregoire, Jean
    Kappelhoff, Reinhild
    Labbe, David P.
    Bachvarov, Dimcho
    Tetu, Bernard
    Overall, Christopher M.
    Bairati, Isabelle
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (06)
  • [27] LONG-TERM SURVIVAL IN WOMEN WITH HIGH-GRADE SEROUS OVARIAN CANCER: INTERPLAY BETWEEN RB1 AND BRCA1/2
    Saner, F. A. M.
    Garsed, D. W.
    Beach, J. A.
    Pandey, A.
    Fereday, S.
    Alsop, K.
    Wouters, M. C. A.
    Traficante, N.
    Pearce, C. L.
    Pike, M. C.
    de Fazio, A.
    Ramus, S. J.
    Kobel, M.
    Goode, E. L.
    Nelson, B. H.
    Bowtell, D. D. L.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A146 - A147
  • [28] Immune microenvironment characteristics of primary tumor predict long-term disease-free survival in high-grade serous ovarian cancer (HGSOC)
    Jones, Wendell
    Ganapathi, Mahrukh
    Michener, Chad
    Ganapathi, Ram N.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [29] Hormonal receptor expression and clinical outcome in ovarian high-grade serous carcinoma
    George, S.
    Sowamber, R.
    Dodds, L.
    Jordan, S. E.
    Paudel, I.
    Huang, M.
    Pinto, A.
    Schlumbrecht, M. P.
    Shaw, P.
    Slomovitz, B. M.
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 154 : 73 - 73
  • [30] Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
    Lana E. Kandalaft
    Denarda Dangaj Laniti
    George Coukos
    [J]. Nature Reviews Cancer, 2022, 22 : 640 - 656